Alector Inc
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
ALEC$2.46+7.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
| March 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $37,973 | $33,021 |
| Marketable securities | 316,578 | 380,376 |
| Prepaid expenses and other current assets | 12,099 | 11,420 |
| Total current assets | 366,650 | 424,817 |
| Property and equipment, net | 16,207 | 17,145 |
| Operating lease right-of-use assets | 19,082 | 19,951 |
| Restricted cash | 1,846 | 1,846 |
| Other assets | 4,518 | 4,544 |
| Total assets | $408,303 | $468,303 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $2,326 | $2,215 |
| Accrued clinical supply costs | 5,831 | 6,989 |
| Accrued liabilities | 17,320 | 28,890 |
| Deferred revenue, current portion | 21,850 | 23,663 |
| Payable to collaboration partner | 9,045 | 5,914 |
| Refund liability to collaboration partner, current portion | 44,571 | 48,634 |
| Operating lease liabilities, current portion | 8,830 | 8,754 |
| Total current liabilities | 109,773 | 125,059 |
| Deferred revenue, long-term portion | 170,308 | 172,169 |
| Long-term debt | 9,464 | 9,389 |
| Refund liability to collaboration partner, long-term portion | — | 9,276 |
| Operating lease liabilities, long-term portion | 22,754 | 24,376 |
| Other long-term liabilities | 1,394 | 1,234 |
| Total liabilities | 313,693 | 341,503 |
| Commitments and contingencies (Note 4) | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 99,992,600 and 99,085,888 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 9 | 9 |
| Additional paid-in capital | 964,008 | 955,657 |
| Accumulated other comprehensive income | 191 | 261 |
| Accumulated deficit | (869,598) | (829,127) |
| Total stockholders’ equity | 94,610 | 126,800 |
| Total liabilities and stockholders’ equity | $408,303 | $468,303 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.